| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Consultations in Molecular Diagnostics |
From the Departments of Molecular Genetics
* and Advanced Diagnostics Information Technology,
Quest Diagnostics Incorporated, Nichols Institute, San Juan Capistrano, California
Abstract
Two mutations in the MCOLN1 mucolipidosis IV (ML IV) gene represent 
95% of the mutations in Ashkenazi-Jewish patients with ML IV. The mutations, a splice site mutation (IVS3-2A>G) and an 6.4-kb deletion (511del6434), account for 72% and 23% of ML IV alleles in this population, respectively. An automated high-throughput assay was developed using the 5'-nuclease (TaqMan) method for the simultaneous detection of both mutations in a single reaction. Three fluorescent probes specifically detected wild-type, IVS3-2A>G, and 511del6434 alleles in each reaction real-time. Data collected were automatically analyzed, and genotype results were uploaded into a laboratory information management system. The assay was validated using genomic controls, demonstrating high robustness and accuracy. Carrier screening of 10,527 samples revealed 77 heterozygote carriers of IVS3-2A>G, 25 heterozygote carriers of 511del6434, and two compound heterozygote of both mutant alleles. The frequency of mutated alleles was 0.73% for IVS3-2A>G and 0.24% for 511del6434. The combined carrier frequency was 1:103 with predicted disease incidence of 1:42,436 individuals in this population, slightly lower than previously described frequencies. This automated high-throughput assay is labor saving, because two mutations can be detected in a single reaction. The method has potential for use in other assays requiring simultaneous detection of two mutations.
Mucolipidosis IV (ML IV) is an autosomal recessive neurodegenerative lysosomal storage disease in which 80 to 90% of patients are of Ashkenazi-Jewish (AJ) descent.1, 2 Published heterozygote carrier frequencies in the AJ population vary from 1:62 to 1:127 (Online Mendelian Inheritance in Man, no. 252650).3, 4, 5 Although there is some heterogeneity, affected individuals generally exhibit psychomotor retardation, and most patients do not progress beyond a developmental age of 1 to 2 years. Other symptoms include characteristic opthalmological abnormalities (Online Mendelian Inheritance in Man).3, 5, 6
ML IV is caused by loss of function mutations in the MCOLN1 gene.8
The gene has been mapped to chromosome 19 and codes for a potential membrane channel.1, 3, 8
Two predominant mutations were identified in ML IV patients of AJ descent, IVS3-2A>G and 511del6434, which together account for more than 95% of ML IV chromosomes. The IVS3-2A>G mutation causes aberrant mRNA splicing and skipping of exon 3 and accounts for 72% of AJ ML IV chromosomes. The 511del6434 is a large deletion that spans exon 1 through exon 7 and represents 23% of AJ ML IV chromosomes.1, 8
Other rare mutations have been described in patients of Ashkenazi and non-Ashkenazi descent.1, 8
Previous genotyping methods have relied on polymerase chain reaction-restriction fragment length polymorphism,4 polymerase chain reaction (PCR)-single strand conformational polymorphism,9 or allele-specific oligonucleotide hybridization.5 These techniques and methods, however, are not easily amenable to automation or high-throughput genotyping required in a commercial genotyping laboratory. A commercially available kit from Elucigene (Tepnel Diagnostics, Oxford, UK) using the amplification-refractory mutation system can be used to detect several mutations more prevalent in the AJ population, including both ML IV mutations. Recently, a method that relies on the Tag-It system was developed by Tm Bioscience (Toronto, Canada). Because of its high multiplexing capabilities, the Tag-It method for detecting ML IV mutations was developed as part of a panel for detection of mutations more prevalent in AJ, such as Tay-Sachs and Canavan diseases. The Tag-It AJ panel assay detects more than 33 mutations and, therefore, is much more demanding in terms of successful even multiplex amplification and allele-specific primer extension reactions.
We developed a one-step, single-tube method for the detection of wild-type and both AJ mutant alleles using the TaqMan platform. We describe the development and validation of the method and the initial results from screening >10,000 samples submitted for carrier testing. We also report on the results of a platform comparison of our method to the Tag-It method.
Materials and Methods
Oligonucleotides and Reagents
Table 1
shows primers and probes used in this study. TaqMan MGB probes and TaqMan Universal PCR Master Mix (2x) were from Applied Biosystems (Foster City, CA). An ABI 7900 with sequence detection system software (Applied Biosystems) was used for amplification and data analysis. DNA was extracted using Qiagen (Valencia, CA) or Genovision Robotic workstations according to the manufacturers’ instructions. Reagents and DNA were dispensed manually or by using an automated pipetting workstation. For the clinical laboratory assay, we used a Biomek2000 (Beckman Coulter, Fullerton, CA).
|
PCR Conditions
Reactions contained 25 µl of 2x TaqMan Universal PCR master mix, 0.9 µmol/L of each primer (Table 1)
, 0.2 µmol/L of IVS3-2A>G wild-type (wt) probe, 0.36 µmol/L IVS3-2A>G probe, 0.5 µmol/L 511del6434 probe (Table 1)
, 2x bovine serum albumin (NEB, Ipswich, MA), 4x Q solution (Qiagen), 0.5 µl of 25 mmol/L MgCl2 solution (Qiagen), 4 µl DNA, and H2O (Sigma Chemical Co., St. Louis, MO) to a final reaction volume of 50 µl. Master mix was aliquoted into optical reaction plates and sealed with an optical adhesive seal (Applied Biosystems). All plates included positive and negative DNA controls. Assays were run on the ABI 7900 instrument in the real-time mode using the following conditions: 50°C for 2 minutes, 95°C for 10 minutes, followed by 45 cycles of 95°C for 15 seconds, 60°C for 1 minute.
Data Analysis
Data contained in the results table [which displays cycle threshold (Ct) values] and in the multicomponent results table (which displays the signals generated in relative fluorescent units) were used. Proprietary software was developed to analyze the data and provide allele assignments based on the Ct value and signal generation. Using Ct alone can lead to misinterpretation of background signals in an empty well that did not receive reagents and can generate false values for Ct. Manual review of the data can prevent this error because the fluorescent signals generated using the multicomponent plot will indicate no amplification in the no reagent well. Calculations using both Ct and fluorescence provide quality assurance of the allele call. The automated allele calls were recorded as wt/wt, heterozygous for either mutation, compound heterozygous, or homozygous mutant for either allele.
Platform Comparison
We analyzed 583 patient samples and 55 wt/wt or positive control samples for the IVS3-2A>G and 511del6434 mutations using the Tag-It mutation detection kit for Ashkenazi-Jewish mutations from Tm Bioscience (Toronto, Ontario). This detection methodology utilizes multiplex PCR followed by allele-specific primer extension. The mutations are detected using the Luminex platform and Tm Bioscience’s proprietary universal tag system. Samples were analyzed on the Tag-It platform using the manufacturer’s protocol.
Results and Discussion
Experimental Design and Assay Validations
An assay was designed for detecting the IVS3-2A>G and 511del6434 mutations in MCOLN1 using 5'-exonuclease TaqMan real-time PCR. As the deletion encompasses exons 1 to 7, a probe to detect the presence of IVS3-2A>G wt allele would by default indicate the absence of the 511del6434 mutation in at least one allele. To detect the presence of the deletion, two PCR primers were designed that flank the deletion break points. If the deletion is absent, the conditions of the PCR will not allow amplification of a large 6.4-kb fragment. In the presence of a deletion, a 200-bp product will be generated, and a probe specific for that amplicon will hybridize, indicating the presence of the deletion. Thus, each reaction can have one or two amplicon products (depending on the absence or presence of the deletion). The strategy is shown in Figure 1
.
|
2.5 hours). This enables a rapid turn around time, as fast as 1-day turn-around time if extraction is performed on the same day.
To validate the assay, cell lines containing the following genotypes were used: homozygous IVS3-2A>G, homozygous 511del6434, and compound heterozygous IVS3-2A>G/511del6434. Heterozygote DNA samples were made by mixing equal concentrations of the homozygous mutant sample DNAs from Coriell Cell Repositories with a wt/wt sample. These controls were used for optimizing assay conditions. As shown in Figure 2
, the assay was able to detect the presence of wt/wt, IVS3-2A>G/wt, and 511del6434/wt heterozygotes as well as the homozygous IVS3-2A>G/IVS3-2A>G and 511del6434/511del6434 mutations. Furthermore, the assay was able to detect the compound heterozygote IVS3-2A>G/511del6434. A validation panel consisting of 89 samples was assembled after anonymizing the samples, and two laboratory personnel performed the assay validations a total of three times using two different lots of reagents. All samples were detected and genotyped correctly, including all controls in all three setups with one exception in one validation experiment. In one sample, the Ct value was positive but the fluorescence units were very low, possibly because of a pipetting error. In a clinical setting this sample would be repeated because of very low relative fluorescent unit signals.
|
. In a wt/wt sample, only the VIC probe was detected, while the FAM and TET were not. In heterozygotes the VIC and either the FAM (wt/IVS3-2A>G) or the TET (wt/511del6434) signals were detected. Homozygous IVS3-2A>G samples showed only the FAM signals, and homozygous 511del6434 sample showed only TET signals. In a compound heterozygous IVS3-2A>G/511del6434 sample, the FAM and the TET signals were detected (Figure 2)
.
Allele Frequency in Our Tested Populations
Samples submitted to Quest Diagnostics for ML IV carrier testing were analyzed using the TaqMan method. In each assay setup, positive controls representing wt/wt, IVS3-2A>G/wt, 511del6434/wt, and IVS3-2A>G/511del6434 were included. We analyzed 10,527 consecutive samples submitted for carrier testing, and the results are shown in Table 2
. The results for 2006 of these cases were published previously.10
Seventy-seven chromosomes of 21,054 carried the IVS3-2A>G mutation for a mutant allele frequency of 0.37% while 25 chromosomes carried the 511del6434 mutation for an allele frequency of 0.12%. The heterozygote carrier frequency was 0.73% for the IVS3-2A>G and 0.24% for the 511del6434; the combined carrier frequency was 0.97% or 1:103 individuals and a predicted disease incidence of 1:42,436. We also identified two cases of affected females. In these cases, the probands were 20 and 14 months old. Genotyping using the method we developed showed that the patients carried compound heterozygosity of the two mutated alleles. No cases harboring homozygous mutations of either allele were detected.
|
7 hours after PCR. The utility of the Tag-It system is for multiplex detection of several alleles. In summary, both the TaqMan and the Tag-It system detected the same number of mutations indicating the sensitivity of both methods. In the expanding field of genetic testing, development of accurate high-throughput automated assays is desirable for the ease of use, minimization of human error, and rapid turn-around time. We chose the TaqMan assay platform to develop a rapid assay for the detection of the prevalent mutant alleles in the MCOLN1 gene in AJ. Our method combines a single tube assay for the detection of both alleles, IVS3-2A>G3 and 511del6434 mutations. No further manipulation, such as enzymatic digestion or allele-specific oligonucleotide, is needed as has been previously described.4, 5 Additionally, automated PCR setup on a liquid handling robotic workstation minimizes hands-on manipulation, and the ability of our method for automated allele calls removes human bias in interpreting results. Automated uploading of the results into the laboratory information system eliminates transcription errors. Both the TaqMan assay and the Tag-It detection method performed well for mutation detection, with the TaqMan assay having the advantage of simplicity and ease of operation and the Tag-It system showing the advantage for multiplex detection of several alleles, but with the increase in the number of steps for sample analysis.
When examining the data generated from analysis of greater than 10,000 patient samples, our results are similar to those of Bargal and colleagues2
and Edelmann and colleagues5
with regard to overall carrier frequency (1:103 in our set versus 1:127 in Edelmann et al). The distribution of the mutations is also consistent with those of other reports in the literature (Table 2)
. We have no way of assuring all our samples are derived from AJ individuals. The frequency of the IVS3-2A>G is approximately three times that of the 511del6434. Previous data published by this laboratory10
reported a carrier frequency of 1:182, although the number of samples was lower (n = 2006). The larger number of samples tested in the current study yielded a carrier frequency more consistent with other reports (Table 2)
. The same is true for the proportion of the two mutated alleles tested in the current study, as our results here are consistent with other published studies.
The carrier frequency of 1:103 is not as high as that of Tay-Sachs (1:36) or Gaucher disease (1:19), but it is close to Niemann-Pick (1:125) and Fanconi anemia type C (1:108), and higher than Bloom syndrome (1:164, Strom et al10 ). Whether a recommendation is required for population-based screening for ML IV in AJs, as is the case for Tay-Sachs disease, is up for debate and will require evaluation of the potential benefits and costs involved.
Acknowledgments
We thank Christina Deeter and Elaina Kapoor for technical assistance; Joy B. Redman, M.S., Genetic Counselor, for clinical information on affected patients; and the reviewers for their helpful comments.
Footnotes
Address reprint requests to Feras M. Hantash, M.S., Ph.D., Department of Molecular Genetics, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA 92690. E-mail: feras.x.hantash{at}questdiagnostics.com
Current address of S.C.O.: Biocept, Inc., 5810 Nancy Ridge Dr., Suite 150, San Diego, CA 92121.
Accepted for publication September 12, 2005.
References
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
